TrialAmerican heart journal2015

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study.

Dean J Kereiakes et al.PubMed ↗Publisher ↗

No numbers read from the abstract.